In recent years,cryotherapy has gained increasing acceptance as a treatment for prostate cancer,offering complementary therapeutic benefits when combined with radical surgery and radiotherapy.Despite the potential for...In recent years,cryotherapy has gained increasing acceptance as a treatment for prostate cancer,offering complementary therapeutic benefits when combined with radical surgery and radiotherapy.Despite the potential for surgical complications,it stands as a safe and viable therapeutic modality.Cryotherapy provides an efficient approach for elderly patients,especially those with compromised physical conditions and individuals experiencing recurrence after initial treatment.It has shown promise in extending survival periods and improving the overall quality of life for these patients.This article aims to comprehensively examine the developmental trajectory,surgical techniques,indications,therapeutic outcomes,and potential complications associated within prostate cancer treatment.展开更多
To gain beneficial effects in the management of high-risk prostate cancer, an integrated approach that combines local therapy and androgen deprivation therapy （ADT） was used. We compared biochemical responses betwee...To gain beneficial effects in the management of high-risk prostate cancer, an integrated approach that combines local therapy and androgen deprivation therapy （ADT） was used. We compared biochemical responses between primary cryosurgical ablation of the prostate （CSAP） combined with prolonged ADT and radiation combined with ADT, which is the established modality in high-risk disease. A total of 33 high-risk patients received CSAP combined with ADT for 3 months before and up to 24 months after treatment. This patient group was matched with another 33 patients who had undergone three-dimensional conformal radiation therapy （3D-CRT） with the same protocol for ADT. Biochemical recurrence （BCR） was assessed by the American Society for Therapeutic Radiation Oncology （ASTRO） definition, the Phoenix definition and a prostate-specific antigen （PSA） cutoff of 0.5 ng mL^-1. Median follow-up was 61.0 ± 11.9 months for the CSAP ＋ ADT group and 86.0±15.8 months for the 3D-CRT ＋ ADT group. In the CSAP group, major complications including rectourethral fistula and incontinence were not noted. In the CSAP ＋ ADT group, 57.0% had BCR using the ASTRO definition, 21.2% using the Phoenix definition and 54.5% using a PSA cutoff of 0.5 ng mL^-1. In the 3D-CRT ＋ ADT group, 54.5%, 21.2% and 54.5% had BCR using the ASTRO, Phoenix and PSA definition, respectively. In the CSAP ＋ ADT group, the BCR-free survival （BRFS） was 54 ± 10 months using the ASTRO definition, 65 ± 5 months using the Phoenix definition and 51 ± 4 months using a PSA cutoff of 0.5 ng mL-1. In the 3D-CRT ＋ ADT group, the BRFS was 68 ± 12, 93 ± 19 and 70 ± 18 months using the ASTRO, Phoenix and PSA definition, respectively. By the log-rank test, the BRFS values for each group were not statistically different. This intermediate-term result indicated that primary CSAP combined with prolonged ADT offers a parallel biochemical response compared with radiotherapy in high-risk prostate cancer.展开更多
Objective To evaluate term efficacy of focal cryoablation for localized single lesion prostate cancer and protection of erectile function. Methods From June 2008 to December 2009,12 patients with localized single lesi...Objective To evaluate term efficacy of focal cryoablation for localized single lesion prostate cancer and protection of erectile function. Methods From June 2008 to December 2009,12 patients with localized single lesion prostate cancer were treated with focal cryoabla-展开更多
基金supported by the National Natural Science Foundation of China(No.82203320).
文摘In recent years,cryotherapy has gained increasing acceptance as a treatment for prostate cancer,offering complementary therapeutic benefits when combined with radical surgery and radiotherapy.Despite the potential for surgical complications,it stands as a safe and viable therapeutic modality.Cryotherapy provides an efficient approach for elderly patients,especially those with compromised physical conditions and individuals experiencing recurrence after initial treatment.It has shown promise in extending survival periods and improving the overall quality of life for these patients.This article aims to comprehensively examine the developmental trajectory,surgical techniques,indications,therapeutic outcomes,and potential complications associated within prostate cancer treatment.
文摘To gain beneficial effects in the management of high-risk prostate cancer, an integrated approach that combines local therapy and androgen deprivation therapy （ADT） was used. We compared biochemical responses between primary cryosurgical ablation of the prostate （CSAP） combined with prolonged ADT and radiation combined with ADT, which is the established modality in high-risk disease. A total of 33 high-risk patients received CSAP combined with ADT for 3 months before and up to 24 months after treatment. This patient group was matched with another 33 patients who had undergone three-dimensional conformal radiation therapy （3D-CRT） with the same protocol for ADT. Biochemical recurrence （BCR） was assessed by the American Society for Therapeutic Radiation Oncology （ASTRO） definition, the Phoenix definition and a prostate-specific antigen （PSA） cutoff of 0.5 ng mL^-1. Median follow-up was 61.0 ± 11.9 months for the CSAP ＋ ADT group and 86.0±15.8 months for the 3D-CRT ＋ ADT group. In the CSAP group, major complications including rectourethral fistula and incontinence were not noted. In the CSAP ＋ ADT group, 57.0% had BCR using the ASTRO definition, 21.2% using the Phoenix definition and 54.5% using a PSA cutoff of 0.5 ng mL^-1. In the 3D-CRT ＋ ADT group, 54.5%, 21.2% and 54.5% had BCR using the ASTRO, Phoenix and PSA definition, respectively. In the CSAP ＋ ADT group, the BCR-free survival （BRFS） was 54 ± 10 months using the ASTRO definition, 65 ± 5 months using the Phoenix definition and 51 ± 4 months using a PSA cutoff of 0.5 ng mL-1. In the 3D-CRT ＋ ADT group, the BRFS was 68 ± 12, 93 ± 19 and 70 ± 18 months using the ASTRO, Phoenix and PSA definition, respectively. By the log-rank test, the BRFS values for each group were not statistically different. This intermediate-term result indicated that primary CSAP combined with prolonged ADT offers a parallel biochemical response compared with radiotherapy in high-risk prostate cancer.
文摘Objective To evaluate term efficacy of focal cryoablation for localized single lesion prostate cancer and protection of erectile function. Methods From June 2008 to December 2009,12 patients with localized single lesion prostate cancer were treated with focal cryoabla-
